Selected research
Industry Research
Anti-Migraine Drugs Industry Research Report 2026
Market perspective
The global Anti-Migraine Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Anti-Migraine Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Anti-Migraine Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Anti-Migraine Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Anti-Migraine Drugs include Allergan, Endo, Impax Laboratories, AstraZeneca, Amgen, Bayer, GlaxoSmithKline, Pfizer and Eli Lilly, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Anti-Migraine Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anti-Migraine Drugs Market by Company
Allergan
Endo
Impax Laboratories
AstraZeneca
Amgen
Bayer
GlaxoSmithKline
Pfizer
Eli Lilly
Merck
Johnson & Johnson
Teva
Eisai
Abbott
Anti-Migraine Drugs Segment by Type
Ergots
Triptans
Others
Anti-Migraine Drugs Segment by Application
Women
Men
Anti-Migraine Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Migraine Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Migraine Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Migraine Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Anti-Migraine Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Anti-Migraine Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Anti-Migraine Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ergots
- Triptans
- Others
Applications
- Women
- Men
Companies covered
- Allergan
- Endo
- Impax Laboratories
- AstraZeneca
- Amgen
- Bayer
- GlaxoSmithKline
- Pfizer
- Eli Lilly
- Merck
- Johnson & Johnson
- Teva
- Eisai
- Abbott
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Anti-Migraine Drugs Market Size (2021-2032)
- 2.2.2 Global Anti-Migraine Drugs Sales (2021-2032)
- 2.2.3 Global Anti-Migraine Drugs Market Average Price (2021-2032)
- 2.3 Anti-Migraine Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Ergots
- 2.3.3 Triptans
- 2.3.4 Others
- 2.4 Anti-Migraine Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Women
- 2.4.3 Men
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Anti-Migraine Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Anti-Migraine Drugs Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Anti-Migraine Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Anti-Migraine Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Anti-Migraine Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Anti-Migraine Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Anti-Migraine Drugs, Product Type & Application
- 3.8 Global Manufacturers of Anti-Migraine Drugs, Established Date
- 3.9 Global Anti-Migraine Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Allergan
- 4.1.1 Allergan Company Information
- 4.1.2 Allergan Business Overview
- 4.1.3 Allergan Anti-Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Allergan Anti-Migraine Drugs Product Portfolio
- 4.1.5 Allergan Recent Developments
- 4.2 Endo
- 4.2.1 Endo Company Information
- 4.2.2 Endo Business Overview
- 4.2.3 Endo Anti-Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Endo Anti-Migraine Drugs Product Portfolio
- 4.2.5 Endo Recent Developments
- 4.3 Impax Laboratories
- 4.3.1 Impax Laboratories Company Information
- 4.3.2 Impax Laboratories Business Overview
- 4.3.3 Impax Laboratories Anti-Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Impax Laboratories Anti-Migraine Drugs Product Portfolio
- 4.3.5 Impax Laboratories Recent Developments
- 4.4 AstraZeneca
- 4.4.1 AstraZeneca Company Information
- 4.4.2 AstraZeneca Business Overview
- 4.4.3 AstraZeneca Anti-Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 AstraZeneca Anti-Migraine Drugs Product Portfolio
- 4.4.5 AstraZeneca Recent Developments
- 4.5 Amgen
- 4.5.1 Amgen Company Information
- 4.5.2 Amgen Business Overview
- 4.5.3 Amgen Anti-Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Amgen Anti-Migraine Drugs Product Portfolio
- 4.5.5 Amgen Recent Developments
- 4.6 Bayer
- 4.6.1 Bayer Company Information
- 4.6.2 Bayer Business Overview
- 4.6.3 Bayer Anti-Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bayer Anti-Migraine Drugs Product Portfolio
- 4.6.5 Bayer Recent Developments
- 4.7 GlaxoSmithKline
- 4.7.1 GlaxoSmithKline Company Information
- 4.7.2 GlaxoSmithKline Business Overview
- 4.7.3 GlaxoSmithKline Anti-Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 GlaxoSmithKline Anti-Migraine Drugs Product Portfolio
- 4.7.5 GlaxoSmithKline Recent Developments
- 4.8 Pfizer
- 4.8.1 Pfizer Company Information
- 4.8.2 Pfizer Business Overview
- 4.8.3 Pfizer Anti-Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Pfizer Anti-Migraine Drugs Product Portfolio
- 4.8.5 Pfizer Recent Developments
- 4.9 Eli Lilly
- 4.9.1 Eli Lilly Company Information
- 4.9.2 Eli Lilly Business Overview
- 4.9.3 Eli Lilly Anti-Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Eli Lilly Anti-Migraine Drugs Product Portfolio
- 4.9.5 Eli Lilly Recent Developments
- 4.10 Merck
- 4.10.1 Merck Company Information
- 4.10.2 Merck Business Overview
- 4.10.3 Merck Anti-Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Merck Anti-Migraine Drugs Product Portfolio
- 4.10.5 Merck Recent Developments
- 4.11 Johnson & Johnson
- 4.11.1 Johnson & Johnson Company Information
- 4.11.2 Johnson & Johnson Business Overview
- 4.11.3 Johnson & Johnson Anti-Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Johnson & Johnson Anti-Migraine Drugs Product Portfolio
- 4.11.5 Johnson & Johnson Recent Developments
- 4.12 Teva
- 4.12.1 Teva Company Information
- 4.12.2 Teva Business Overview
- 4.12.3 Teva Anti-Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Teva Anti-Migraine Drugs Product Portfolio
- 4.12.5 Teva Recent Developments
- 4.13 Eisai
- 4.13.1 Eisai Company Information
- 4.13.2 Eisai Business Overview
- 4.13.3 Eisai Anti-Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Eisai Anti-Migraine Drugs Product Portfolio
- 4.13.5 Eisai Recent Developments
- 4.14 Abbott
- 4.14.1 Abbott Company Information
- 4.14.2 Abbott Business Overview
- 4.14.3 Abbott Anti-Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Abbott Anti-Migraine Drugs Product Portfolio
- 4.14.5 Abbott Recent Developments
5 Global Anti-Migraine Drugs Market Scenario by Region
- 5.1 Global Anti-Migraine Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Anti-Migraine Drugs Sales by Region: 2021-2032
- 5.2.1 Global Anti-Migraine Drugs Sales by Region: 2021-2026
- 5.2.2 Global Anti-Migraine Drugs Sales by Region: 2027-2032
- 5.3 Global Anti-Migraine Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Anti-Migraine Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Anti-Migraine Drugs Revenue by Region: 2027-2032
- 5.4 North America Anti-Migraine Drugs Market Facts & Figures by Country
- 5.4.1 North America Anti-Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Anti-Migraine Drugs Sales by Country (2021-2032)
- 5.4.3 North America Anti-Migraine Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Anti-Migraine Drugs Market Facts & Figures by Country
- 5.5.1 Europe Anti-Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Anti-Migraine Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Anti-Migraine Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Anti-Migraine Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Anti-Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Anti-Migraine Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Anti-Migraine Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Anti-Migraine Drugs Market Facts & Figures by Country
- 5.7.1 South America Anti-Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Anti-Migraine Drugs Sales by Country (2021-2032)
- 5.7.3 South America Anti-Migraine Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Anti-Migraine Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Anti-Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Anti-Migraine Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Anti-Migraine Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Anti-Migraine Drugs Sales by Type (2021-2032)
- 6.1.1 Global Anti-Migraine Drugs Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Anti-Migraine Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Anti-Migraine Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Anti-Migraine Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Anti-Migraine Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Anti-Migraine Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Anti-Migraine Drugs Sales by Application (2021-2032)
- 7.1.1 Global Anti-Migraine Drugs Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Anti-Migraine Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Anti-Migraine Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Anti-Migraine Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Anti-Migraine Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Anti-Migraine Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Anti-Migraine Drugs Value Chain Analysis
- 8.1.1 Anti-Migraine Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Anti-Migraine Drugs Production Mode & Process
- 8.2 Anti-Migraine Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Anti-Migraine Drugs Distributors
- 8.2.3 Anti-Migraine Drugs Customers
9 Global Anti-Migraine Drugs Analyzing Market Dynamics
- 9.1 Anti-Migraine Drugs Industry Trends
- 9.2 Anti-Migraine Drugs Industry Drivers
- 9.3 Anti-Migraine Drugs Industry Opportunities and Challenges
- 9.4 Anti-Migraine Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst